Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 11
Submit an article Journal homepage
528
Views
23
CrossRef citations to date
0
Altmetric
Drug Profile

Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients

Andrea Bacigalupo Department of Hematology, Ospedale San Martino, Genova, Italy. [email protected]; Department of Hematology, Ospedale San Martino, Genova, Italy. [email protected]
,
Alan Boyd College of Medical and Dental Sciences, University Medical School, Birmingham, UK; College of Medical and Dental Sciences, University Medical School, Birmingham, UK
,
Jackie Slipper Clinigen Group Ltd, Pitcairn House, Crown Square, Burton-on-Trent, DE14 2WW, UK; Clinigen Group Ltd, Pitcairn House, Crown Square, Burton-on-Trent, DE14 2WW, UK
,
Jim Curtis Clinigen Group Ltd, Pitcairn House, Crown Square, Burton-on-Trent, DE14 2WW, UK; Clinigen Group Ltd, Pitcairn House, Crown Square, Burton-on-Trent, DE14 2WW, UK
&
Steve Clissold Content Ed Net, Avenida de Burgos 9 of 4, Madrid, 28036, Spain; Content Ed Net, Avenida de Burgos 9 of 4, Madrid, 28036, Spain
Pages 1249-1264 | Published online: 10 Jan 2014

References

  • Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev. Hematol. 4(4), 437–452 (2011).
  • Pollack M, Heugel J, Xie H et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol. Blood Marrow Transplant. 17(5), 664–673 (2011).
  • Ahmed A. Antiviral treatment of cytomegalovirus infection. Infect. Disord. Drug Targets 11(5), 475–503 (2011).
  • Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153(3), 478–488 (1986).
  • Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41(1), 104–129 (1991).
  • Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48(2), 199–226 (1994).
  • Schreiber A, Härter G, Schubert A, Bunjes D, Mertens T, Michel D. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin. Pharmacother. 10(2), 191–209 (2009).
  • Manischewitz JF, Quinnan GV Jr, Lane HC, Wittek AE. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 34(2), 373–375 (1990).
  • Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49(3), 873–883 (2005).
  • Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23, 689–712 (2010).
  • Scott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 51(1), 89–94 (2007).
  • Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. J. Infect. Dis. 176, 50–58 (1997).
  • Jabs DA, Enger C, Forman M, Dunn JP. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob. Agents Chemother. 42(9), 2240–2244 (1998).
  • Sjövall J, Bergdahl S, Movin G, Ogenstad S, Saarimäki M. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 33(7), 1023–1031 (1989).
  • Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I–II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J. Infect. Dis. 166(3), 473–479 (1992).
  • Stocchi R, Ward KN, Fanin R et al. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica 84(1), 71–79 (1999).
  • Krüger WH, Bohlius J, Cornely OA et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. Ann. Oncol. 16(8), 1381–1390 (2005).
  • Baldanti F, Lilleri D, Gerna G. Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation. Hematol. Oncol. 26(3), 123–130 (2008).
  • Fernández MN. Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors. Br. J. Haematol. 147(2), 161–176 (2009).
  • Nguyen Q, Champlin R, Giralt S et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin. Infect. Dis. 28(3), 618–623 (1999).
  • Pancholi P, Wu F, Della-Latta P. Rapid detection of cytomegalovirus infection in transplant patients. Expert Rev. Mol. Diagn. 4(2), 231–242 (2004).
  • Ljungman P, de la Camara R, Einsele H et al. Recommendations for CMV and HHV-6 management in patients with hematological diseases. Presented at: The Fourth European Conference on Infections in Leukaemia. Juan-les-Pins, France, 9–10 September 2011.
  • Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant. 26(7), 763–767 (2000).
  • Tomblyn M, Chiller T, Einsele H et al.; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant. 15(10), 1143–1238 (2009).
  • Aschan J, Ringdén O, Ljungman P, Lönnqvist B, Ohlman S. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand. J. Infect. Dis. 24(2), 143–150 (1992).
  • Ringdén O, Wilczek H, Lonnqvist B et al. Foscarnet for cytomegalovirus infections. Lancet 325, 1501–1504 (1985).
  • Chang J, Powles R, Singhal S et al. Foscarnet therapy for cytomegalovirus infection after allogeneic bone marrow transplantation. Clin. Infect. Dis. 22(3), 583–584 (1996).
  • Bacigalupo A, van Lint MT, Tedone E et al. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant. 13(6), 753–758 (1994).
  • Bacigalupo A, Bregante S, Tedone E et al. Combined foscarnet–ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 18(Suppl. 2), 110–114 (1996).
  • Asakura M, Ikegame K, Yoshihara S et al. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. Int. J. Hematol. 92(2), 351–359 (2010).
  • Jayaweera DT. Minimising the dosage-limiting toxicities of foscarnet induction therapy. Drug Saf. 16(4), 258–266 (1997).
  • Yamazaki S, Ikuta K, Fujii H et al. [Cytomegalovirus infection after allogeneic stem cell transplantation]. J. Japan. Pediatric Hematol. Society 13, 151–157 (1999).
  • Ishiko Y, Suzuki T, Toyoda Y et al. [Foscarnet for cytomegalovirus infection early after hematopoietic stem cell transplantation]. J. Japan. Pediatr. Hematol. Society 17, 333–339 (2003).
  • Okamoto T, Okada M, Mori A et al. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient. Bone Marrow Transplant. 20(9), 801–803 (1997).
  • Ohta H, Matsuda Y, Tokimasa S et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA. Bone Marrow Transplant. 27(11), 1141–1145 (2001).
  • Kudoh T, Yagi H, Kanazawa T et al. [Mutant cytomegalovirus infection after unrelated allogeneic bone marrow transplantation which needed long term foscarnet therapy]. J. Japan. Pediatric Hematol. Society 19, 79–82 (2005).
  • Razis E, Cook P, Mittelman A, Ahmed T. Treatment of gancyclovir resistant cytomegalovirus with foscarnet: a report of two cases occurring after bone marrow transplantation. Leuk. Lymphoma 12(5–6), 477–480 (1994).
  • Hubacek P, Keslova P, Formankova R et al. Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet. Pediatr. Transplant. 13(7), 919–922 (2009).
  • Ehlert K, Groll AH, Kuehn J, Vormoor J. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin. Padiatr. 218(3), 180–184 (2006).
  • Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N. Engl. J. Med. 325(23), 1601–1607 (1991).
  • Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope–Stanford–Syntex CMV Study Group. N. Engl. J. Med. 324(15), 1005–1011 (1991).
  • Ljungman P, Aschan J, Lewensohn-Fuchs I et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66(10), 1330–1334 (1998).
  • Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin. Microbiol. Rev. 16(4), 647–657 (2003).
  • Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant. 13(6), 783–788 (1994).
  • Ordemann R, Naumann R, Geissler G et al. Foscarnet – an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation? Ann. Hematol. 79(8), 432–436 (2000).
  • Bregante S, Bertilson S, Tedone E et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant. 26(1), 23–29 (2000).
  • Ippoliti C, Morgan A, Warkentin D et al. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant. 20(6), 491–495 (1997).
  • Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS. A pilot Phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr. Blood Cancer 49(3), 306–312 (2007).
  • Reusser P, Einsele H, Lee J et al.; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99(4), 1159–1164 (2002).
  • Moretti S, Zikos P, Van Lint MT et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant. 22(2), 175–180 (1998).
  • Mattes FM, Hainsworth EG, Geretti AM et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J. Infect. Dis. 189(8), 1355–1361 (2004).
  • Ljungman P, Oberg G, Aschan J et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 18(3), 565–568 (1996).
  • Takami A, Mochizuki K, Ito S et al. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation. Transplant. Proc. 39(1), 237–239 (2007).
  • Narimatsu H, Kami M, Kato D et al. Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. Transpl. Infect. Dis. 9(1), 11–15 (2007).
  • Wang H, Zhu L, Xue M, Liu J, Guo Z. Low-dose foscarnet preemptive therapy for cytomegalovirus viremia after haploidentical bone marrow transplantation. Biol. Blood Marrow Transplant. 15(4), 519–520 (2009).
  • Ruiz-Camps I, Len O, de la Cámara R et al.; Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Antivir. Ther. 16(7), 951–957 (2011).
  • Mikulska M, Raiola AM, Bruzzi P et al. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. Biol. Blood Marrow Transplant. 18(1), 92–99 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.